PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22137657-7	2012	injection of DHA (25 and 50mug/mouse) and GW9508 (a GPR40- and GPR120-selective agonist; 0.1 and 1.0mug/mouse) significantly reduced formalin-induced pain behavior.	GW9508	42-48	free fatty acid receptor 4	Mus musculus	63-69	
28446241-11	2017	Reducing GPR120 hypothalamic expression using a lentivirus-based approach resulted in the loss of the anti-inflammatory effect of GW9508 and increased energy efficiency.	GW9508	130-136	free fatty acid receptor 4	Mus musculus	9-15	
28446241-12	2017	Intracerebroventricular treatment with the GPR120- and GPR40-specific agonists TUG1197 and TUG905, respectively, resulted in milder effects than those produced by GW9508.	GW9508	163-169	free fatty acid receptor 4	Mus musculus	43-49	
27489163-7	2016	Treatment of Ffar4 agonist (GW9508) recapitulated the thermogenic activation of EPA by increasing oxygen consumption rate, brown-specific marker genes, and miR-30b and 378, which were abrogated in Ffar4-silenced cells.	GW9508	28-34	free fatty acid receptor 4	Mus musculus	13-18	
27489163-7	2016	Treatment of Ffar4 agonist (GW9508) recapitulated the thermogenic activation of EPA by increasing oxygen consumption rate, brown-specific marker genes, and miR-30b and 378, which were abrogated in Ffar4-silenced cells.	GW9508	28-34	free fatty acid receptor 4	Mus musculus	197-202	
24673159-3	2014	We report here that DHA and the GPR120 agonist, GW9508, activate cPLA2 and cyclooxygenase 2 (COX-2), and cause prostaglandin E2 (PGE2) release in a murine macrophage cell line RAW264.7 and in human primary monocyte-derived macrophages.	GW9508	48-54	free fatty acid receptor 4	Mus musculus	32-38	
16702987-3	2006	Here, we present the first description of GW9508, a small-molecule agonist of the fatty acid receptors GPR40 and GPR120.	GW9508	42-48	free fatty acid receptor 4	Mus musculus	113-119	
31129318-3	2019	METHODS: The present study investigates the influence of prolonged treatment with GW9508 - agonist of FFAR1 and FFAR4 - on the development of atherosclerosis plaque in apoE-knockout mice, using morphometric and molecular methods.	GW9508	82-88	free fatty acid receptor 4	Mus musculus	112-117	
31129318-6	2019	CONCLUSIONS: Prolonged administration of GW9508 resulted in significant amelioration of atherogenesis, providing evidence that the strategy based on macrophage phenotype switching toward an M2-like activation state via stimulation of FFAR1/FFAR4 receptors holds promise for a new approach to the prevention or treatment of atherosclerosis.	GW9508	41-47	free fatty acid receptor 4	Mus musculus	240-245	
26853521-1	2016	Here, we assessed the effects of long-chain fatty acids (LCFAs) and the LCFA receptor agonist GW9508 on the transcription of the gonadotropin subunit genes Cga, Lhb and Fshb because LCFA receptor GPR120 was observed in mouse gonadotropes in our recent study.	GW9508	94-100	free fatty acid receptor 4	Mus musculus	196-202	
24673159-4	2014	DHA and GW9508 activate cPLA2 via GPR120 receptor, G protein Galphaq and scaffold protein beta-arrestin 2.	GW9508	8-14	free fatty acid receptor 4	Mus musculus	34-40	
24222669-5	2014	Addition of GW-9508 (a GPR120 chemical agonist) and alpha-linolenic acid (a natural ligand for GPR120) inhibited the secretion of ghrelin by ~50 and 70%, respectively.	GW9508	12-19	free fatty acid receptor 4	Mus musculus	23-29	
24222669-8	2014	Moreover, we observed that the inhibitory effect of GW-9508 on ghrelin secretion was blocked by a small interfering RNA (siRNA) targeting the sequence of GPR120.	GW9508	52-59	free fatty acid receptor 4	Mus musculus	154-160